Screener
Haemonetics HAE Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Haemonetics’s reported figures.
Based on trailing twelve months.
The source filing: Haemonetics’s 10-Q, filed February 5, 2026. Open the filing →
- Filed
- Feb 5, 2026, 6:05 AM EST
- Fiscal quarter
- Q3 FY2026
- Calendar quarter
- Q4 2025
- Accession
- 0000313143-26-000010
FAQ
- What is Haemonetics's return on equity?
- Haemonetics (HAE) reported return on equity of 19.3% in Q4 2025.
- How has Haemonetics's return on equity changed year-over-year?
- Haemonetics's return on equity increased by 37.2% year-over-year, from 14.1% to 19.3%.
- What is the long-term trend for Haemonetics's return on equity?
- Over 4 years (2021 to 2025), Haemonetics's return on equity has grown at a 11.8% compound annual growth rate (CAGR), from 12.1% to 18.8%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Haemonetics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude